Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.

Human pathology - 1 Oct 2012

Hussein Yaser R, Sood Anil K, Bandyopadhyay Sudeshna, Albashiti Bassam, Semaan Assaad, Nahleh Zeina, Roh Juwon, Han Hee Dong, Lopez-Berestein Gabriel, Ali-Fehmi Rouba

Abstract excerpt

The polycomb group protein, enhancer of zeste homolog 2, is a transcriptional repressor involved in cell cycle regulation and has been linked to aggressive breast cancer. We examined the clinical and biological significance of enhancer of zeste homolog 2 expression in triple-negative breast cance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Polycomb Repressive Complex 2

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 22436627
DOI: 10.1016/j.humpath.2011.12.004
PMCID: PMC4194857

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22436627-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.PMID 22436627Read ↗

Overexpression of enhancer of zests homolog 2 in lymphoma.Semantic proximity Read ↗

Long non‐coding RNA ZEB2‐AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple‐negative breast cancer by epigenetically activating ZEB2Semantic proximity Read ↗

EZH2 expands breast stem cells through activation of NOTCH1 signalingSemantic proximity Read ↗

Enhancer of Zeste Homolog 2 Overexpression Has a Role in the Development of Anaplastic Thyroid CarcinomasSemantic proximity Read ↗

Genome–wide binding of transcription factor ZEB1 in triple‐negative breast cancer cellsSemantic proximity Read ↗

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersSemantic proximity Read ↗

Activation of the <i>Enhancer of Zeste Homologue 2</i> Gene by the Human Papillomavirus E7 OncoproteinSemantic proximity Read ↗

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.Semantic proximity Read ↗

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)Semantic proximity Read ↗

ZHX2 Promotes HIF1α Oncogenic Signaling in Triple-Negative Breast CancerSemantic proximity Read ↗

Cloning of a Human Homolog of theDrosophila Enhancer of zesteGene (EZH2) That Maps to Chromosome 21q22.2Semantic proximity Read ↗

EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.